Stock Research Report for Aurobindo Pharma Ltd
Stock score of Aurobindo Pharma Ltd moved up by 1 in a week on a 10 point scale (Source: Refinitiv). Get detailed report on Aurobindo Pharma Ltd by subscribing to ETPrime.
Get 4000+ Stock Reports worth₹ 1,499* with ETPrimeat no extra cost for you
*As per competitive benchmarking of annual price. T&C apply
Make Investment decisions
with proprietary stock scores on earnings, fundamentals, relative valuation, risk and price momentum
Find new Trading ideas
with weekly updated scores and analysts forecasts on key data points
In-Depth analysis
of company and its peers through independent research, ratings, and market data
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its Key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. The Company is marketing its products globally in approximately 150 countries. The Company's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltda, and others.
